Tista' taqra bil- Malti.
A prospective Covid-19 vaccine being developed by the University of Oxford has shown highly promising results in a trial, appearing to be safe and effective in triggering an immune response, the BBC is reporting.
The trial involved 1,077 people who were administered the vaccine, which has been dubbed ChAdOx1 nCoV-19. However, larger trials will be required to determine if the immune response created is enough to offer protection from the coronavirus.
The vaccine is made from a genetically engineered virus that causes the common old in chimpanzees, modified so that it cannot cause infections and to make it appear more similar to the coronavirus. Its developers transferred genetic instructions for the coronavirus’s “spike protein,” which the virus uses to enter human cells, to the vaccine.
Though no dangerous side effects were observed, around 70% of participants in the trial developed headaches or a fever.
The main purpose of this trial was to ensure that the vaccine is safe enough to administer, but larger trials – which will extend to countries where levels of coronavirus are particularly high – will seek to determine whether it is effective.
The UK has already struck a deal to acquire 100 million doses of the prospective vaccine.